Natalia Krasteva

Dr. Natalia Krasteva

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2019 in Nanotoxicology
Verified
Journal Article
Closed access
HSHuimin Shao
Huimin Shao
ZHZhongyu Han
Zhongyu Han
NKNatalia Krasteva
Natalia Krasteva
Dayong WangDayong Wang
Dayong Wang
The molecular response of animals to nanoplastic particles is still largely unclear. In this study, we employed a modified prolonged exposure system to investigate the molecular response of Caenorhabditis elegans to nanopolystyrene particles. Exposure to nanopolystyrene particles (1 μg/L) significantly decreased expressions of daf-2 encoding an insulin receptor, age-1 encoding a PI3K, and akt-1 encoding an Akt/PKB, and increased expression of daf-16 encoding a FOXO transcriptional factor in insulin signaling pathway. Among these genes, mutation of daf-2, age-1, or akt-1 induced a resistance to toxicity of nanopolystyrene particles, whereas mutation of daf-16 induced a susceptibility to the toxicity of nanopolystyrene particles. RNAi knockdown of daf-16 could further suppress the resistance of daf-2, age-1, or akt-1 mutant to the toxicity of nanopolystyrene particles. The insulin signaling pathway acted in intestinal cells to regulate the toxicity of nanopolystyrene particles. Moreover, sod-3 encoding a manganese superoxide dismutase, mtl-1 encoding a metallothionein, and gpd-2 encoding a glyceraldehyde-3-phosphate dehydrogenase were identified as downstream targeted genes for daf-16 in the regulation of toxicity of nanopolystyrene particles. Therefore, a signaling cascade of DAF-2-AGE-1-AKT-1-DAF-16-SOD-3/MTL-1/GPD-2 was identified in response to nanopolystyrene particles in nematodes. Additionally, this signaling cascade in the insulin signaling pathway may mediate a protective response for nematodes against the adverse effects from nanopolystyrene particles.

7 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NKNatalia Krasteva
Natalia Krasteva
Milena GeorgievaMilena Georgieva
Milena Georgieva
Colorectal cancer (CRC) is a global health problem responsible for 10% of all cancer incidences and 9.4% of all cancer deaths worldwide. The number of new cases increases per annum, whereas the lack of effective therapies highlights the need for novel therapeutic approaches. Conventional treatment methods, such as surgery, chemotherapy and radiotherapy, are widely applied in oncology practice. Their therapeutic success is little, and therefore, the search for novel technologies is ongoing. Many efforts have focused recently on the development of safe and efficient cancer nanomedicines. Nanoparticles are among them. They are uniquewith their properties on a nanoscale and hold the potential to exploit intrinsic metabolic differences between cancer and healthy cells. This feature allows them to induce high levels of toxicity in cancer cells with little damage to the surrounding healthy tissues. Graphene oxide is a promising 2D material found to play an important role in cancer treatments through several strategies: direct killing and chemosensitization, drug and gene delivery, and phototherapy. Several new treatment approaches based on nanoparticles, particularly graphene oxide, are currently under research in clinical trials, and some have already been approved. Here, we provide an update on the recent advances in nanomaterials-based CRC-targeted therapy, with special attention to graphene oxide nanomaterials. We summarise the epidemiology, carcinogenesis, stages of the CRCs, and current nanomaterials-based therapeutic approaches for its treatment.

24 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
Kamelia Hristova-PanushevaKamelia Hristova-Panusheva
Kamelia Hristova-Panusheva
Charilaos XenodochidisCharilaos Xenodochidis
Charilaos Xenodochidis
Milena GeorgievaMilena Georgieva
Milena Georgieva
NKNatalia Krasteva
Natalia Krasteva
Nanotechnology has emerged as a transformative force in oncology, facilitating advancements in site-specific cancer therapy and personalized oncomedicine. The development of nanomedicines explicitly targeted to cancer cells represents a pivotal breakthrough, allowing the development of precise interventions. These cancer-cell-targeted nanomedicines operate within the intricate milieu of the tumour microenvironment, further enhancing their therapeutic efficacy. This comprehensive review provides a contemporary perspective on precision cancer medicine and underscores the critical role of nanotechnology in advancing site-specific cancer therapy and personalized oncomedicine. It explores the categorization of nanoparticle types, distinguishing between organic and inorganic variants, and examines their significance in the targeted delivery of anticancer drugs. Current insights into the strategies for developing actively targeted nanomedicines across various cancer types are also provided, thus addressing relevant challenges associated with drug delivery barriers. Promising future directions in personalized cancer nanomedicine approaches are delivered, emphasising the imperative for continued optimization of nanocarriers in precision cancer medicine. The discussion underscores translational research’s need to enhance cancer patients’ outcomes by refining nanocarrier technologies in nanotechnology-driven, site-specific cancer therapy.

22 June 2018 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
MRMingxia Ren
Mingxia Ren
LZLi Zhao
Li Zhao
XDXuecheng Ding
Xuecheng Ding
NKNatalia Krasteva
Natalia Krasteva
QRQi Rui
Qi Rui
Dayong WangDayong Wang
Dayong Wang
Intestinal barrier is crucial for animals against translocation of engineered nanomaterials (ENMs) into secondary targeted organs. However, the molecular mechanisms for the role of intestinal barrier against ENMs toxicity are still largely unclear. The intestine of Caenorhabditis elegans is a powerful in vivo experimental system for the study on intestinal function. In this study, we investigated the molecular basis for intestinal barrier against toxicity and translocation of graphene oxide (GO) using C. elegans as a model animal. Based on the genetic screen of genes required for the control of intestinal development at different aspects using intestine-specific RNA interference (RNAi) technique, we identified four genes (erm-1, pkc-3, hmp-2 and act-5) required for the function of intestinal barrier against GO toxicity. Under normal conditions, mutation of any of these genes altered the intestinal permeability. With the focus on PKC-3, an atypical protein kinase C, we identified an intestinal signaling cascade of PKC-3-SEC-8-WTS-1, which implies that PKC-3 might regulate intestinal permeability and GO toxicity by affecting the function of SEC-8-mediated exocyst complex and the role of WTS-1 in maintaining integrity of apical intestinal membrane. ISP-1 and SOD-3, two proteins required for the control of oxidative stress, were also identified as downstream targets for PKC-3, and functioned in parallel with WTS-1 in the regulation of GO toxicity. Using C. elegans as an in vivo assay system, we found that several developmental genes required for the control of intestinal development regulated both the intestinal permeability and the GO toxicity. With the focus on PKC-3, we raised two intestinal signaling cascades, PKC-3-SEC-8-WTS-1 and PKC-3-ISP-1/SOD-3. Our results will strengthen our understanding the molecular basis for developmental machinery of intestinal barrier against GO toxicity and translocation in animals.

24 November 2023 in Experimental Gerontology
Verified
Journal Article
Open access
Milena GeorgievaMilena Georgieva
Milena Georgieva
CXCharilaos Xenodochidis
Charilaos Xenodochidis
NKNatalia Krasteva
Natalia Krasteva
Recent scientific interest has been directed towards age-related diseases, driven by the significant increase in global life expectancy and the growing population of individuals aged 65 and above. The ageing process encompasses various biological, physiological, environmental, psychological, behavioural, and social changes, leading to an augmented susceptibility to chronic illnesses. Cardiovascular, neurological, musculoskeletal, liver and oncological diseases are prevalent in the elderly. Moreover, ageing individuals demonstrate reduced regenerative capacity and decreased tolerance towards therapeutic interventions, including organ transplantation. Liver diseases, such as non-alcoholic fatty liver disease, alcoholic liver disease, hepatitis, fibrosis, and cirrhosis, have emerged as significant public health concerns. Paradoxically, these conditions remain underestimated despite their substantial global impact. Age-related factors are closely associated with the severity and unfavorable prognosis of various liver diseases, warranting further investigation to enhance clinical management and develop novel therapeutic strategies. This comprehensive review focuses specifically on age-related liver diseases, their treatment strategies, and contemporary practices. It provides a detailed account of the global burden, types, molecular mechanisms, and epigenetic alterations underlying these liver pathologies.

1 June 2002 in Biomaterials
Verified
Journal Article
Closed access
NKNatalia Krasteva
Natalia Krasteva
UHUlrike Harms
Ulrike Harms
WAWolfgang Albrecht
Wolfgang Albrecht
BSBarbara Seifert
Barbara Seifert
MHMichael Hopp
Michael Hopp
Thomas GrothThomas Groth
Thomas Groth